Background: HIV infection and HAART trigger genetic and functional mitochondrial alterations leading to cell death and adverse clinical manifestations. Mitochondrial dynamics enable mitochondrial turnover and degradation of damaged mitochondria, which may lead to apoptosis.
Introduction
In developed countries, mortality and morbidity rates associated with HIV have dramatically decreased, turning this infection into a chronic disease. 1 This has been achieved thanks to HAART, a combined antiretroviral treatment that usually comprises two NRTIs combined with either a PI or an NNRTI. 2, 3 Both the virus and its treatment have been demonstrated to cause mitochondrial toxicity by either interference in mitochondrial function or apoptosis. 4, 5 It has been proposed that these molecular disturbances are one of the aetiopathological bases of the secondary effects of HIV infection and therapy, including myopathy, hyperlactataemia, lactic acidosis, peripheral neuropathy and lipodystrophy, as well as infertility and obstetric problems. [6] [7] [8] Furthermore, pregnancies in HIVinfected women are associated with an increased risk of adverse obstetric outcomes, including preterm delivery, pre-eclampsia, V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. stillbirth, low birth weight and intrauterine growth restriction (IUGR). [9] [10] [11] [12] Mitochondrial and apoptosis-related alterations have been described in pregnancies among HIV-infected women, including decreased mitochondrial DNA (mtDNA) levels and consequent mitochondrial dysfunction in different tissues, including oocytes, PBMCs and adipose tissue, as well as in fetal cord blood mononuclear cells (CBMCs) of exposed children. [13] [14] [15] [16] [17] Mitochondria are highly dynamic organelles, the morphology, structure and constitution of which are continually changing by fission and fusion processes. 18 The frequency of these processes determines the quality as well as the morphology of mitochondria. Additionally, mitochondrial dynamics regulate mitochondrial bioenergetics, calcium signalling, mtDNA stability, mitochondrial quality, the generation of oxidative stress and cellular stress response. 19 Mitochondrial fusion enables mitochondrial renewal, recycling and turnover by promoting component exchange between altered and healthy mitochondria. 20 Mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) are required to promote fusion of two neighbouring mitochondria. On the other hand, mitochondrial fission is mediated by dynaminrelated protein 1 (Drp1), which divides a mitochondrion into two. Fission helps by splitting healthy from defective mitochondria. Damaged mitochondria should be further recycled or degraded through mitophagy; 21 otherwise, apoptosis begins. Considering the importance of these processes, abnormalities in mitochondrial dynamics and apoptosis have been suggested to occur early during the pathogenesis of many diseases. 22, 23 Several human pathologies, including cancer, Parkinson's disease, Alzheimer's disease and cardiovascular disorders, have been linked to abnormalities in proteins that govern mitochondrial fission or fusion phenomena or apoptosis development. 20, 24 Previous studies support interference in cell and mitochondrial function by both HIV and HAART, leading to adverse clinical effects. 4, 5 However, few data are available about mitochondrial dynamics in the context of infectious diseases. To date, only in vitro models demonstrating HIV-1 viral protein R (Vpr) interaction with apoptosis and mitochondrial dynamics have been reported. 25 No ex vivo studies have been performed to assess the influence of HIV on mitochondrial dynamics or the relation between HAART and mitochondrial fusion and fission events and their potential association with an increased frequency of adverse obstetric outcomes in HIV-infected pregnant women on HAART.
The aim of this study was to evaluate Mfn2 and Drp1 levels, as markers of mitochondrial dynamics, together with caspase 3 content, indicative of apoptosis, in pregnancies among HIV-infected women on HAART and determine their potential association with obstetric and neonatal complications.
Materials and methods

Design
We performed a controlled single-site, observational study without intervention to determine the influence of mitochondrial dynamics and apoptosis on adverse obstetric outcomes of pregnancies in HIV-infected women on HAART. First, we compared longitudinal changes during pregnancy (from the first trimester of gestation to delivery) in PBMCs of HIV-infected pregnant women on HAART and uninfected pregnant controls. Second, CBMCs of uninfected but exposed newborns and the placenta of HIVinfected pregnant women on HAART were cross-sectionally compared at delivery with uninfected controls.
Patients
Twenty-six asymptomatic HIV-infected pregnant women on HAART and 18 uninfected controls were prospectively included in the first trimester of gestation during routine prenatal care in the Hospital Clinic of Barcelona (Spain) over 18 months. Inclusion criteria were age 18 years, single pregnancy, delivery at .22 weeks of gestation and, for HIV patients, previous diagnosis of HIV infection. No patients taking drugs potentially toxic to mitochondria or with a family history of mitochondrial disease were included. Epidemiological, immunovirological, therapeutic, obstetric, perinatal and experimental data were collected in a database.
Ethics
All participants provided written consent to participate in the study. The Ethics Committee of our hospital approved the study (reference code 2009/5118), which was performed following the Declaration of Helsinki guidelines.
Data collection
The epidemiological data included maternal age, ethnicity, illegal substance abuse and alcohol consumption. Immunovirological data for HIV-infected pregnant women on HAART included plasma HIV viral load, CD4 T-cell count and time from HIV infection to delivery. The therapeutic data collected included accumulated time of specific drug consumption (NRTI, NNRTI or PI) and stratification of HIV-infected pregnant women according to HAART use during pregnancy.
Therapy was administered to all HIV-infected pregnant women following international guidelines. Women naive to HAART before pregnancy started HAART (double-NRTI schedule and either PI or NNRTI) during the second trimester of gestation and continued for at least 6 months after delivery to prevent mother-to-child transmission (MTCT).
Data regarding obstetric and perinatal outcomes included pre-eclampsia (new onset of hypertension of .140 mmHg systolic or .90 mmHg diastolic blood pressure and .300 mg protein/24 h urine after 20 weeks of gestation), fetal death (.22 weeks of pregnancy), gestational age at delivery, preterm birth (,37 weeks of gestation), birth weight, small for gestational age (,10th percentile), 5 min Apgar score ,7 and global adverse perinatal outcome (including preterm birth, IUGR and preterm premature rupture of membranes).
Finally, maternal, neonatal and placental mitochondrial dynamics and apoptosis measures were collected in the first trimester of gestation and at delivery.
Samples
Twenty millilitres of maternal peripheral blood was obtained by antecubital vein puncture and collected in EDTA tubes, both in the first trimester of pregnancy (second to third months) and immediately after delivery. At delivery, 20 mL of neonatal cord blood was obtained and collected in EDTA tubes.
Maternal PBMCs and neonatal CBMCs were isolated by a Ficoll gradient procedure and cryopreserved at #80+5 C until analysis. Placentas were obtained at delivery and immediately frozen at #80+5 C until analysis. A homogenate of placental tissue (5% w/v) was prepared in mannitol buffer. Protein content was measured in PBMCs, CBMCs and placental homogenates using the bicinchoninic acid colorimetric assay (Thermo Scientific assay kit) to normalize experimental measures.
Mitochondrial studies
Mitochondrial dynamics
Mfn2 and Drp1 protein levels were examined by western blot analysis. Twenty micrograms of total protein from PBMCs, CBMCs and placenta was Mitochondrial dynamics and apoptosis in HIV pregnancies JAC separated using 7%/13% SDS-PAGE and transferred to nitrocellulose membranes (iBlot Gel Transfer Stacks, Life Technologies), which were hybridized with anti-Mfn2 (1:2000; Abcam, Cambridge, UK) and/or anti-Drp1 (1:500; Santa Cruz, CA, USA). Quantification of Mfn2 (82 kDa) and Drp1 (80 kDa) was normalized by the content of b-actin protein (47 kDa) as a total cell protein loading control. The ImageQuantLD program was used to quantify chemiluminescence. Mfn2/b-actin levels were interpreted as a marker of mitochondrial fusion development 26 and Drp1/b-actin levels as a marker of mitochondrial fission events. 27 
Apoptosis
Western blot analysis was performed with 20 lg of total cell protein of PBMCs, CBMCs and placenta as described above. Nitrocellulose membranes were incubated with anti-caspase 3 (1:1000; Cell Signaling, MA, USA). Active (cleaved) caspase 3 protein expression (17-19 kDa) was normalized and quantified. The results were expressed as caspase 3/b-actin relative content and interpreted as a marker of advanced apoptosis-related events. 28 
Statistical analysis
Clinical and epidemiological parameters were expressed as mean and range and experimental results as mean and SEM or as a percentage increase/decrease at delivery compared with the first trimester of pregnancy or compared with controls.
Statistical analysis was performed using the IBM SPSS Statistics 20 program. Non-parametric tests were used to determine case-control differences (Mann-Whitney independent sample analysis) and the OR (v 2 test). Additionally, different correlations were made between experimental and clinical data to assess the dependence of obstetric complications on mitochondrial dynamics or apoptosis imbalance, and the influence of therapeutic or immunovirological conditions on them (Spearman test). A P value ,0.05 was considered significant. Table 1 shows the epidemiological, immunovirological and therapeutic results of patients and controls. No significant differences were observed in epidemiological data between HIV-positive and HIV-negative pregnant women, who were all Caucasian, ranging from 27 to 42 years old. The mean time of HIV infection and of HAART prior to delivery was 98.1 and 52.8 months, respectively. All HIV-infected mothers were on HAART for at least 6 months prior to delivery to avoid MTCT, including those starting HAART during pregnancy (n " 4; 15.4%) and those already on HAART (n " 22; 84.6%). HAART consisted of administering two NRTIs and either one PI (53.8%) or one NNRTI (30.8%). At delivery, all women presented an undetectable viral load. Neither patients nor controls presented clinical manifestations of mitochondrial toxicity. Table 2 shows the obstetric and neonatal outcomes of the study cohorts. All infants were HIV uninfected with no symptoms of mitochondrial toxicity, but those exposed in utero to HIV received 6 weeks of post-natal zidovudine chemoprophylaxis to reduce MTCT. The two cohorts showed similar gestational ages at delivery (37.9 versus 38.9 weeks), but pregnancies in HIV-infected women on HAART showed a higher trend to preterm birth (23.1% versus 11.1%), reduced birth weight (2974 versus 3080 g), higher frequency of small-for-gestational-age newborns (23.1% versus 5.6%) and significantly increased global adverse obstetric outcomes (61.5% versus 16.7%; P " 0.043).
Results
Clinical data
Perinatal outcomes
Mitochondrial dynamics
Mfn2/b-actin expression was significantly reduced, by 47.89+9.86%, in PBMCs of HIV-infected pregnant women on HAART compared with controls during the first trimester of pregnancy (0.74+0.14 versus 1.42+0.27, P " 0.025; Figure 1a and Figure S1a , available as Supplementary data at JAC Online). However, at delivery, Mfn2/ b-actin expression was similar in the two cohorts (14.89+25.53% increased in HIV-infected pregnant women on HAART compared with controls; 0.54+0.12 versus 0.47+0.09; P " 0.705; Figure 1a and Figure S1a ). Guitart-Mampel et al.
On longitudinal analysis, a significant decrease, of 202.13+57.45%, was observed in Mfn2/b-actin levels in PBMCs of control pregnancies from the first trimester of pregnancy to delivery (1.42+0.27 versus 0.47+0.09; P " 0.003; Figure 1a and Figure S1a ). This significant decrease was not observed in HIV-infected pregnant women on HAART (37.04+25.93% decrease; 0.74+0.14 versus 0.54+0.12; P " 0.173; Figure 1a and Figure S1a ), since they presented significantly reduced levels compared with controls from the 
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JAC first trimester of pregnancy. CBMC Mfn2/b-actin levels were conserved in HIV-and HAART-exposed newborns (increase of 60.71+39.29% versus controls; 0.45+0.11 versus 0.28+0.07, P " 0.292; Figure 1b and Figure S1b ). Finally, Mfn2/b-actin levels were significantly reduced, by 88.43+3.50%, in placentas of HIV-infected pregnant women on HAART compared with controls (0.86+0.26 versus 7.43+3.04; P " 0.004; Figure 1c and Figure S1c ), as were Drp1/b-actin levels (by 95.93+1.63%) compared with controls (0.06+0.02 versus 0.91+0.22; P " 0.011; Figure 1d and Figure S1c ).
Apoptosis
PBMCs from pregnancies in HIV-infected women on HAART presented a significant increase in caspase 3/b-actin levels, of 97.92+31.25% (0.19+0.03 versus 0.10+0.03; P " 0.036; Figure 2a and Figure S1a ), in the first trimester of gestation and of 123.53+35.29% at delivery (0.38+0.06 versus 0.17+0.05; P " 0.024; Figure 2a and Figure S1a ), compared with controls.
On longitudinal analysis, caspase 3/b-actin content in PBMCs of pregnancies among HIV-infected women on HAART rose significantly, by 50.00+7.89%, from the first trimester of gestation to delivery (0.19+0.03 versus 0.38+0.06; P " 0.030; Figure 2a and Figure S1a ). This ratio also increased, albeit not significantly, in the control cohort (43.53+17.65%; 0.10+0.03 versus 0.17+0.05; P " 0.304; Figure 2a and Figure S1a) .
Caspase 3/b-actin levels in neonatal CBMCs from pregnancies in HIV-infected women on HAART remained similar to those of controls (0.48+0.14 versus 0.47+0.17; P " 1.000; Figure 2b and Figure S1b ) and placentas from pregnancies in HIV-infected women on HAART showed a slight trend towards an increase (33.33+30.56%) compared with controls (0.48+0.11 versus 0.36+0.12, respectively; P " 0.44; Figure 2c and Figure S1c ).
Associations between experimental and clinical features
At an immunological level, CD4! T cell counts in HIV-infected pregnant women on HAART at delivery significantly and positively correlated with Mfn2 levels in CBMCs from their newborns (R 2 " 0.696, P " 0.002), suggesting that proper maternal immunovirological status helps to prevent an imbalance in mitochondrial dynamics (Figure 3a ). 
Guitart-Mampel et al.
Positive correlations at the limit of significance were observed in pregnancies among HIV-infected women on HAART at delivery between apoptosis (both in maternal PBMCs and neonatal CBMCs) compared with pregestational NRTI treatment (R 2 " 0.113, P " 0.044 and R 2 " 0.113, P " 0.047, respectively), suggesting the dependence of apoptosis development on NRTI toxicity (Figure 3b  and c) .
Additionally, a positive correlation was found between apoptosis in CBMCs of HIV-and HAART-exposed newborns and maternal age at delivery, strengthening the involvement of ageing in cell damage and survival (P " 0.037, data not shown). Additionally, significant positive correlations were observed in Mfn2 levels of maternal PBMCs or caspase 3/b-actin levels between the first trimester of pregnancy and delivery, suggesting the usefulness of these biomarkers for first-trimester screening (P " 0.005 and P " 0.001, respectively; data not shown).
Finally, despite significantly increased incidence of adverse perinatal outcomes in pregnancies among HIV-infected women on HAART, no correlation was found between an imbalance in mitochondrial dynamics or apoptosis-related events and obstetric outcomes.
Discussion
The aetiopathology of obstetric disarrangements in pregnancies among HIV-infected women remains under debate, but mitochondrial and apoptosis-related disturbances have previously been associated with adverse clinical effects of HIV infection and its treatment. [9] [10] [11] [12] Mitochondrial dynamics is the mechanism by which damaged mitochondria (which may finally trigger apoptosis) are recycled. Impairment of mitochondrial dynamics and apoptosis has previously been associated with disease. [6] [7] [8] However, mitochondrial dynamics and apoptosis deregulation in the context of human pregnancies, HIV infection and obstetric problems have never been assessed.
Previous in vitro studies have reported a reduction in Mfn2 and Drp1 expression mediated by Vpr, 24 which can be integrated on mitochondria, leading to mitochondrial fragmentation and apoptosis. 24, [29] [30] [31] [32] Although no study has described the involvement of HAART in mitochondrial dynamics, mitochondrial toxicity has been attributed to the NRTI component of this multidrug therapy by interfering in mtDNA replication, which may finally lead to cell death by apoptosis. 25 The present work demonstrates an alteration in the studied markers of mitochondrial dynamics and apoptosis in pregnancies among HIV-infected women on HAART. Additionally, the risk of adverse events in this cohort was demonstrated by trends towards increased rates of preterm birth, reduced birth weight and smallfor-gestational-age newborns, and a significantly higher frequency of global adverse perinatal outcomes.
In our cohort of HIV-infected pregnant women on HAART we observed a significant decrease in Mfn2 levels in maternal PBMCs in the first trimester of pregnancy, which remained decreased during pregnancy. Similarly, we observed a significant reduction in Mfn2 and Drp1 contents in placentas of pregnancies in HIVinfected women on HAART. As previously described in vitro, Vpr may interfere in mitochondrial dynamics in vivo, but only in tissues in contact with the virus (maternal and placental cells). The fetus is uninfected and thus mitochondrial dynamics remain balanced. Experimental data suggest that decreased Mfn2 expression promotes apoptosis and hampers development by obstructing mitochondrial metabolism and disrupting mitochondrial membrane potential and cellular activity, leading to disordered embryonic development. 26 Consequently, imbalanced fusion and fission processes in pregnancies among HIV-infected women on HAART may underlie poor obstetric outcomes.
Additionally, these HIV-infected pregnant women on HAART present a significant increase in the expression of the apoptotic caspase 3 in PBMCs in both the first trimester of gestation and at delivery, probably mediated by the virus, as previously suggested. 29 Again, maternal PBMCs and placentas show a trend to an increase in apoptosis markers, but the fetus remains unaffected. Apoptosis has been associated with adverse obstetric problems in HIV-infected and uninfected pregnant women Mitochondrial dynamics and apoptosis in HIV pregnancies JAC presenting pre-eclampsia and IUGR. 33 Consequently, apoptosis together with an imbalance in mitochondrial dynamics may also interfere with proper neonatal development.
Interestingly, the HIV-infected cohort received HAART during gestation and consequently viral protein levels, including Vpr, should have been almost undetectable. 34 Thus, the imbalance in the studied markers of mitochondrial dynamics and enhanced apoptosis development observed in pregnancies among HIV-infected women on HAART may likely have been HAART-rather than virus-mediated. Alternatively, Vpr or other viral proteins may develop a toxic function when present in small amounts. In this regard, our findings suggest preserved immunovirological maternal status in association with balanced neonatal mitochondrial dynamics (Mfn2 levels). Additionally, higher exposure to NRTI would be associated with the enhancement of apoptosis development (caspase 3 expression). These associations may suggest that both the virus and its treatment, together with maternal age and other environmental agents, may simultaneously interfere with mitochondrial dynamics or apoptosis. However, further studies are needed to confirm these conclusions.
On the other hand, the association of maternal mitochondrial dynamics or apoptosis (Mfn2 and caspase 3 levels) between the first trimester of gestation and at delivery demonstrates the usefulness of these biomarkers in prenatal screening.
Additionally, Mfn2 levels in PBMCs of uninfected control women decreased from the first trimester of gestation to delivery, achieving values similar to those in HIV-infected pregnant women on HAART, which remained underexpressed during gestation. The physiological decrease in Mfn2 in uninfected pregnant controls has not been described previously. The decrease in this marker of mitochondrial fusion during gestation could be explained by the increase in physiological apoptosis of maternal PBMCs that has been described during pregnancy. 35 The increase in apoptotic expression of caspase 3 in controls during gestation could thereby be associated with mitochondrial fusion and fragmentation, 34 regardless of any viral or drug interference. However, this increase in apoptosis markers in uninfected controls at delivery is pathologically enhanced in HIVinfected pregnant women on HAART after the first trimester of gestation, probably mediated by viral infection or treatment, and may explain the reduced Mfn2 levels observed in pregnancies among HIV-infected women since conception. An increase in apoptosis has also been reported in the placenta of HIVinfected pregnant women, 35 thereby explaining the reduced trends towards reduced Mfn2 content in this cohort. However, an imbalance in studied markers of mitochondrial dynamics or apoptosis was not detected in CBMCs of healthy newborns from pregnancies in HIV-infected women on HAART, probably because they were not infected, thus explaining the unaltered levels of Mfn2 or caspase 3 compared with healthy newborns from control pregnancies. Guitart-Mampel et al.
In conclusion, the increase in caspase 3 in PBMCs of HIVinfected pregnant women on HAART could be interpreted as an increase in apoptosis mediated by a reduction in Mfn2, or a reduction in Mfn2 mediated by an increase in apoptosis. Several reports have associated mitochondrial dynamics and mitochondrial fragmentation with cell apoptosis by describing the interaction among the main proteins governing both processes. 26, [36] [37] [38] Apoptosis promotes deregulation of mitochondrial dynamics, but dysfunction in mitochondrial dynamics also promotes apoptosis in a kind of bilateral feedback. Indeed, deregulation of mitochondrial dynamics and apoptosis likely go hand in hand, contributing to the associated adverse obstetric events observed in pregnancies among HIV-infected women on HAART. Apoptosis has been extensively associated with poor obstetric outcome 33 and our data suggest an additive role for the deregulation of mitochondrial dynamics markers, at least in pregnancies among HIV-infected women on HAART (Figure 4 ).
The present study has several limitations. The inclusion of a control group of non-pregnant HIV-infected women on HAART could have been useful to assess potential gestation interference. Another limitation may be the presence of heterogeneous HAART regimens and times of exposure to HIV or HAART, characteristic of observational studies and personalized treatment interventions, which may disclose findings closer to reality. Additionally, the implication of Vpr or alternative viral proteins in mitochondrial dynamics or apoptosis deregulation will remain speculative, as these proteins are usually quantified in plasma and we did not collect this. Finally, no significant association was found between markers of mitochondrial dynamics or apoptosis-related disturbances and obstetric problems, probably due to the reduced sample size, which hampered statistical power, or to technical limitations in the assessment of some of these markers in certain tissues.
Despite these limitations, our findings demonstrate that pregnancies in HIV-infected women on HAART with adverse obstetric outcomes show altered markers of mitochondrial dynamics and apoptosis development, probably due to viral and HAART exposure, potentially leading to increased mitochondrial fragmentation. The alteration of these mechanisms may trigger adverse obstetric outcomes in pregnancies among HIV-infected women on HAART by interfering in mitochondrial recycling and turnover and contributing to classical mitochondrial and apoptosis-related toxicity induced by the virus and its treatment. Further studies are needed to study the aetiology of obstetric problems in depth to establish new putative biomarkers and potential therapeutic targets.
